Breast carcinoma chemoprevention in the community setting

The United States Preventive Services Task Force recommends that women who are at both high risk for breast carcinoma and low risk for adverse events should receive counseling regarding tamoxifen for chemoprevention. Estimates of the risks and benefits of tamoxifen based on results from clinical trials may not reflect the real‐world experience. The authors determined the prevalence of women in a community‐based cohort who would meet the definition of high risk for breast carcinoma and calculated the number of women needed to screen to determine one for whom the benefits of tamoxifen would outweigh the risks. Baseline incidence also was examined for adverse health events in this community‐based cohort compared with participants in the Breast Cancer Prevention Trial.

[1]  J. Beizer,et al.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. , 2005, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[2]  A. McKay,et al.  Acceptance of tamoxifen chemoprevention by physicians and women at risk , 2005, Cancer.

[3]  Joann G. Elmore,et al.  Mammographic Screening for Breast Cancer , 2003 .

[4]  Sowmya R. Rao,et al.  Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. , 2003, Journal of the National Cancer Institute.

[5]  Joann G Elmore,et al.  Clinical practice. Mammographic screening for breast cancer. , 2003, The New England journal of medicine.

[6]  A. Berg.  Chemoprevention of breast cancer: recommendations and rationale. , 2003, The American journal of nursing.

[7]  J. Costantino,et al.  The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. , 2002, Clinical breast cancer.

[8]  D Spiegelman,et al.  Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.

[9]  G H Guyatt,et al.  Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. , 2000, JAMA.

[10]  B. Hillner,et al.  Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[12]  J. Brock,et al.  Serum concentrations of organochlorine compounds and the subsequent development of breast cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[14]  D. Sackett,et al.  The number needed to treat: a clinically useful measure of treatment effect , 1995, BMJ.

[15]  G. Stemmermann,et al.  The effects of nonresponse in a prospective study of cancer. , 1982, American journal of epidemiology.

[16]  T. Dawber,et al.  Some methodologic problems in the long-term study of cardiovascular disease: Observations on the Framingham study , 1959 .